BofA analyst Travis Steed downgraded Inspire Medical (INSP) to Neutral from Buy with a price target of $53, down from $120.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSP:
- Inspire Medical downgraded to Neutral from Overweight at Piper Sandler
- Inspire Medical Cuts 2026 Outlook Amid Reimbursement Headwinds
- Inspire Medical cuts FY26 adjusted EPS view to 75c-$1.25 from $1.85-$2.35
- Inspire Medical reports Q1 adjusted EPS 10c, consensus (26c)
- INSP Upcoming Earnings Report: What to Expect?